# ASCLEPIuS (NCT04194554)

> A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer

No report yet. It can be ordered.

- Drugs tested: niraparib plus abiraterone plus leuprolide
- Indication: high-risk and node-positive prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04194554
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: University of Michigan Rogel Cancer Center
- Conditions: Prostate Cancer
- Interventions: Niraparib; Leuprolide; Abiraterone Acetate; Stereotactic body radiotherapy (SBRT)
- Enrollment: 102
- Primary outcome: Dose-limiting toxicities (Phase 1)
- Primary outcome: Proportion of patients experiencing biochemical failure

## Indexed commentary on ASCLEPIuS so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X
- 1 podcast episode

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=asclepius-nct04194554